Publications by authors named "Elizabeth A Clutterbuck"

Claim this Profile
S
Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial.
Brama Hanumunthadu, Tesfaye Demissie, Melanie Greenland, Peter Skidmore, Kiarash Tanha, Elizabeth A Clutterbuck

EBioMedicine· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.
Ali Amini, Lucy C Garner, Robert H Shaw, Neil Wrigley Kelly, Sandra Adele, Elizabeth A Clutterbuck

Sci Immunol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine.
Daniel O'Connor, Elizabeth A Clutterbuck, Malick M Gibani, Sagida Bibi, Katherine A Sanders

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Shuo Feng, Sagida Bibi, Parvinder K Aley, Federica Cappuccini, Elizabeth A Clutterbuck

J Infect· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.
Eve Richardson, Sagida Bibi, Florence McLean, Lisa Schimanski, Pramila Rijal, Elizabeth A Clutterbuck

Front Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Eimear Kelly, Melanie Greenland, Philip C S de Whalley, Parvinder K Aley, Emma L Plested, Elizabeth A Clutterbuck

J Infect· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children.
Dmitri Kazmin, Elizabeth A Clutterbuck, Giorgio Napolitani, Amanda L Wilkins, Andrea Tarlton

NPJ Vaccines· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Robert H Shaw, Melanie Greenland, Arabella S V Stuart, Parvinder K Aley, Nick J Andrews, Elizabeth A Clutterbuck

J Infect· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Merryn Voysey, Amy Flaxman, Jeremy Aboagye, Parvinder K Aley, Sandra Belij-Rammerstorfer, Elizabeth A Clutterbuck

Clin Exp Immunol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Alexander J Mentzer, Daniel O'Connor, Sagida Bibi, Irina Chelysheva, Elizabeth A Clutterbuck

Nat Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory T cell profiles in patients with -methyl-ᴅ-aspartate receptor-antibody encephalitis.
Mildred A Iro, Christine S Rollier, Sarosh R Irani, Manish Sadarangani, Adam Al-Diwani, Elizabeth A Clutterbuck

Encephalitis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Robert H Shaw, Xinxue Liu, Arabella S V Stuart, Melanie Greenland, Parvinder K Aley, Elizabeth A Clutterbuck

Lancet Respir Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.
Pauline Versteegen, Alex-Mikael Barkoff, Marta Valente Pinto, Jan van de Kasteele, Aapo Knuutila, Elizabeth A Clutterbuck

Front Immunol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Divergent trajectories of antiviral memory after SARS-CoV-2 infection.
Adriana Tomic, Donal T Skelly, Ane Ogbe, Daniel O'Connor, Matthew Pace, Elizabeth A Clutterbuck

Nat Commun· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Arabella S V Stuart, Robert H Shaw, Xinxue Liu, Melanie Greenland, Parvinder K Aley, Elizabeth A Clutterbuck

Lancet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Maheshi N Ramasamy, Angela M Minassian, Katie J Ewer, Amy L Flaxman, Pedro M Folegatti, Elizabeth A Clutterbuck

Lancet· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Xinxue Liu, Robert H Shaw, Arabella S V Stuart, Melanie Greenland, Parvinder K Aley, Elizabeth A Clutterbuck

Lancet· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, Jeremy Aboagye, Parvinder K Aley, Elizabeth A Clutterbuck

Lancet· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Jordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, Katie J Ewer, Pedro M Folegatti, Elizabeth A Clutterbuck

Nat Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Katie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, Hannah Sharpe, Rebecca Makinson, Elizabeth A Clutterbuck

Nat Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Andrew J Pollard, Odile Launay, Jean-Daniel Lelievre, Christine Lacabaratz, Sophie Grande, Elizabeth A Clutterbuck

Lancet Infect Dis· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Katherine R W Emary, Tanya Golubchik, Parvinder K Aley, Cristina V Ariani, Brian Angus, Elizabeth A Clutterbuck

Lancet· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, Lily Y Weckx, Pedro M Folegatti, Elizabeth A Clutterbuck

Lancet· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Jordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, Katie J Ewer, Pedro M Folegatti, Elizabeth A Clutterbuck

Nat Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Katie J Ewer, Jordan R Barrett, Sandra Belij-Rammerstorfer, Hannah Sharpe, Rebecca Makinson, Elizabeth A Clutterbuck

Nat Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis